Polyrizon Ltd. (NASDAQ:PLRZ) shares are moving higher after the company announced it secured a manufacturing agreement with Eurofins CDMO Amatsiaquitaine.
The Details: Under the agreement, Eurofins will supply Polyrizon with Clinical Trial Material (CTM) for its PL-14 allergy blocker trial.
The clinical trial, expected to commence in 2025, will evaluate the safety and efficacy of PL-14.
Tomer Izraeli, CEO of Polyrizon previously stated that, "We are pleased to have established this partnership with Eurofins CDMO Amatsiaquitaine S.A.S, which strengthens our preparation efforts for the upcoming PL-14 clinical trial. We believe that this collaboration marks a significant milestone in our journey toward providing effective allergy protection solutions to patients."
Polyrizon stock is trading on higher-than-normal volume at 72.09 million. The company's average session volume over the past 100 days is about 556.58 thousand.
PLRZ Price Action: At the time of writing, Polyrizon stock is trading 240.9% higher at $3.55, according to data from Benzinga Pro.
Image: Michal Jarmoluk from Pixabay
